X4 Pharmaceuticals
XFOR
35 hedge funds and large institutions have $296M invested in X4 Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.
400% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 5
133% more funds holding
Funds holding: 15 → 35 (+20)
84% more capital invested
Capital invested by funds: $161M → $296M (+$135M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.01% less ownership
Funds ownership: 0.42% → 0.42% (-0.01%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.85M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.64M |
| 3 |
First Eagle Investment Management
New York
|
+$2.01M |
| 4 |
State Street
Boston,
Massachusetts
|
+$911K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$786K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.49M |
| 2 |
DM
Deerfield Management
New York
|
-$1.68M |
| 3 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$504K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$460K |
| 5 |
Millennium Management
New York
|
-$299K |
XFOR Hedge Fund Activity: Q1 2018 in Review
35 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2018, worth a combined $296M — up 84% from $161M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new XFOR positions and 5 closed out — a net gain of 20 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $2.85M. The largest seller was Sphera Funds Management, cutting an estimated $2.49M.
- 35 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2018, up from 15 in Q4 2017.
- Funds reported $296M of X4 Pharmaceuticals stock for Q1 2018, up 84% quarter-over-quarter.
- 25 funds opened new X4 Pharmaceuticals positions in Q1 2018 and 5 closed out, a net change of +20 holders.
- The largest X4 Pharmaceuticals buyer in Q1 2018 was BlackRock, an estimated $2.85M added.
- The largest X4 Pharmaceuticals seller in Q1 2018 was Sphera Funds Management, an estimated $2.49M sold.
Based on aggregated 13F filings for Q1 2018.